The latest announcement is out from Acrux Limited ( (AU:ACR) ).
Acrux Limited has received a $1.73 million advance from Radium Capital related to its FY25 R&D Tax Incentive. This funding provides early access to the expected rebate, supporting product development and working capital management, and is secured against the anticipated rebate from the Australian Taxation Office.
More about Acrux Limited
Acrux Limited is a specialty pharmaceutical company focused on developing and commercializing topically applied pharmaceutical products. With 25 years of experience, the company has successfully marketed products worldwide, particularly in the United States. Acrux leverages its skilled workforce, on-site laboratories, and GMP manufacturing suite to formulate and develop affordable topical generic products. The company is open to collaboration and commercial partnerships.
YTD Price Performance: 33.33%
Average Trading Volume: 1,000
Technical Sentiment Signal: Buy
Current Market Cap: $6.15M
See more insights into ACR stock on TipRanks’ Stock Analysis page.